Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Herpes B virus replication and viral lesions in the liver of a cynomolgus macaque which died from severe disease with rapid onset.

Pöhlmann S, Suntz M, Akimkin V, Bleyer M, Kaul A.

J Med Primatol. 2017 Oct;46(5):256-259. doi: 10.1111/jmp.12269. Epub 2017 Apr 25.

PMID:
28439900
2.

Identification of type I and type II interferon-induced effectors controlling hepatitis C virus replication.

Metz P, Dazert E, Ruggieri A, Mazur J, Kaderali L, Kaul A, Zeuge U, Windisch MP, Trippler M, Lohmann V, Binder M, Frese M, Bartenschlager R.

Hepatology. 2012 Dec;56(6):2082-93. doi: 10.1002/hep.25908. Epub 2012 Oct 14.

PMID:
22711689
3.

Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment.

Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Bühler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R.

Cell Host Microbe. 2011 Jan 20;9(1):32-45. doi: 10.1016/j.chom.2010.12.002.

4.

Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus.

Diegelmann J, Beigel F, Zitzmann K, Kaul A, Göke B, Auernhammer CJ, Bartenschlager R, Diepolder HM, Brand S.

PLoS One. 2010 Dec 8;5(12):e15200. doi: 10.1371/journal.pone.0015200.

5.

Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics.

Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, Kallis S, Zayas M, Lohmann V, Luban J, Bartenschlager R.

PLoS Pathog. 2009 Aug;5(8):e1000546. doi: 10.1371/journal.ppat.1000546. Epub 2009 Aug 14. Erratum in: PLoS Pathog. 2009 Sep;5(9). doi: 10.1371/annotation/29dffb2a-5d37-4196-b166-b0b15bc2f3fd. Lopez, Margarita Zayas [corrected to Zayas, Margarita].

6.

Development and evaluation of a FACS-based medium-throughput assay for HCV entry inhibitors.

Ziegler S, Kronenberger B, Albrecht BA, Kaul A, Gamer AL, Klein CD, Hartmann RW.

J Biomol Screen. 2009 Jul;14(6):620-6. doi: 10.1177/1087057109337161. Epub 2009 Jun 16.

PMID:
19531666
7.

A reporter cell line for rapid and sensitive evaluation of hepatitis C virus infectivity and replication.

Iro M, Witteveldt J, Angus AG, Woerz I, Kaul A, Bartenschlager R, Patel AH.

Antiviral Res. 2009 Aug;83(2):148-55. doi: 10.1016/j.antiviral.2009.04.007. Epub 2009 May 3.

PMID:
19397930
8.

Adaptation of the hepatitis C virus to cell culture.

Kaul A, Wörz I, Bartenschlager R.

Methods Mol Biol. 2009;510:361-72. doi: 10.1007/978-1-59745-394-3_27.

PMID:
19009275
9.

Role of the hepatitis C virus core+1 open reading frame and core cis-acting RNA elements in viral RNA translation and replication.

Vassilaki N, Friebe P, Meuleman P, Kallis S, Kaul A, Paranhos-Baccalà G, Leroux-Roels G, Mavromara P, Bartenschlager R.

J Virol. 2008 Dec;82(23):11503-15. doi: 10.1128/JVI.01640-08. Epub 2008 Sep 17.

10.

Identification of terfenadine as an inhibitor of human CD81-receptor HCV-E2 interaction: synthesis and structure optimization.

Holzer M, Ziegler S, Albrecht B, Kronenberger B, Kaul A, Bartenschlager R, Kattner L, Klein CD, Hartmann RW.

Molecules. 2008 May 7;13(5):1081-110.

11.

Enhancement of genotype 1 hepatitis C virus replication by bile acids through FXR.

Scholtes C, Diaz O, Icard V, Kaul A, Bartenschlager R, Lotteau V, André P.

J Hepatol. 2008 Feb;48(2):192-9. Epub 2007 Dec 3.

PMID:
18096266
12.

Cell culture adaptation of hepatitis C virus and in vivo viability of an adapted variant.

Kaul A, Woerz I, Meuleman P, Leroux-Roels G, Bartenschlager R.

J Virol. 2007 Dec;81(23):13168-79. Epub 2007 Sep 19.

13.

Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses.

Koutsoudakis G, Kaul A, Steinmann E, Kallis S, Lohmann V, Pietschmann T, Bartenschlager R.

J Virol. 2006 Jun;80(11):5308-20.

14.

Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.

Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R.

Proc Natl Acad Sci U S A. 2006 May 9;103(19):7408-13. Epub 2006 May 1.

15.

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.

Paeshuyse J, Kaul A, De Clercq E, Rosenwirth B, Dumont JM, Scalfaro P, Bartenschlager R, Neyts J.

Hepatology. 2006 Apr;43(4):761-70.

PMID:
16557546
16.

Dissecting the interferon-induced inhibition of hepatitis C virus replication by using a novel host cell line.

Windisch MP, Frese M, Kaul A, Trippler M, Lohmann V, Bartenschlager R.

J Virol. 2005 Nov;79(21):13778-93.

17.

Replication of the hepatitis C virus in cell culture.

Bartenschlager R, Kaul A, Sparacio S.

Antiviral Res. 2003 Oct;60(2):91-102. Review.

PMID:
14638404
18.

A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.

Vrolijk JM, Kaul A, Hansen BE, Lohmann V, Haagmans BL, Schalm SW, Bartenschlager R.

J Virol Methods. 2003 Jun 30;110(2):201-9.

PMID:
12798249
19.

Hepatitis C virus RNA replication is resistant to tumour necrosis factor-alpha.

Frese M, Barth K, Kaul A, Lohmann V, Schwärzle V, Bartenschlager R.

J Gen Virol. 2003 May;84(Pt 5):1253-9.

PMID:
12692291
20.

Persistent and transient replication of full-length hepatitis C virus genomes in cell culture.

Pietschmann T, Lohmann V, Kaul A, Krieger N, Rinck G, Rutter G, Strand D, Bartenschlager R.

J Virol. 2002 Apr;76(8):4008-21.

Supplemental Content

Loading ...
Support Center